Antibacterial carbonic anhydrase inhibitors targeting Vibrio cholerae enzymes.

IF 4.6 2区 医学 Q1 PHARMACOLOGY & PHARMACY Expert Opinion on Therapeutic Targets Pub Date : 2024-07-01 Epub Date: 2024-07-19 DOI:10.1080/14728222.2024.2369622
Mohammad Sadegh Gheibzadeh, Clemente Capasso, Claudiu T Supuran, Reza Zolfaghari Emameh
{"title":"Antibacterial carbonic anhydrase inhibitors targeting <i>Vibrio cholerae</i> enzymes.","authors":"Mohammad Sadegh Gheibzadeh, Clemente Capasso, Claudiu T Supuran, Reza Zolfaghari Emameh","doi":"10.1080/14728222.2024.2369622","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cholera is a bacterial diarrheal disease caused by pathogen bacteria Vibrio cholerae, which produces the cholera toxin (CT). In addition to improving water sanitation, oral cholera vaccines have been developed to control infection. Besides, rehydration and antibiotic therapy are complementary treatment strategies for cholera. ToxT regulatory protein activates transcription of <i>CT</i> gene, which is enhanced by bicarbonate (HCO<sub>3</sub><sup>-</sup>).</p><p><strong>Areas covered: </strong>This review delves into the genomic blueprint of V. <i>cholerae</i>, which encodes for α-, β-, and γ- carbonic anhydrases (CAs). We explore how the CAs contribute to the pathogenicity of V. <i>cholerae</i> and discuss the potential of CA inhibitors in mitigating the disease's impact.</p><p><strong>Expert opinion: </strong>CA inhibitors can reduce the virulence of bacteria and control cholera. Here, we reviewed all reported CA inhibitors, noting that α-CA from V. <i>cholerae</i> (VchCAα) was the most effective inhibited enzyme compared to the β- and γ-CA families (VchCAβ and VchCAγ). Among the CA inhibitors, acyl selenobenzenesulfonamidenamides and simple/heteroaromatic sulfonamides were the best VchCA inhibitors in the nM range. It was noted that some antibacterial compounds show good inhibitory effects on all three bacterial CAs. CA inhibitors belonging to other classes may be synthesized and tested on VchCAs to harness cholera.</p>","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2024.2369622","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cholera is a bacterial diarrheal disease caused by pathogen bacteria Vibrio cholerae, which produces the cholera toxin (CT). In addition to improving water sanitation, oral cholera vaccines have been developed to control infection. Besides, rehydration and antibiotic therapy are complementary treatment strategies for cholera. ToxT regulatory protein activates transcription of CT gene, which is enhanced by bicarbonate (HCO3-).

Areas covered: This review delves into the genomic blueprint of V. cholerae, which encodes for α-, β-, and γ- carbonic anhydrases (CAs). We explore how the CAs contribute to the pathogenicity of V. cholerae and discuss the potential of CA inhibitors in mitigating the disease's impact.

Expert opinion: CA inhibitors can reduce the virulence of bacteria and control cholera. Here, we reviewed all reported CA inhibitors, noting that α-CA from V. cholerae (VchCAα) was the most effective inhibited enzyme compared to the β- and γ-CA families (VchCAβ and VchCAγ). Among the CA inhibitors, acyl selenobenzenesulfonamidenamides and simple/heteroaromatic sulfonamides were the best VchCA inhibitors in the nM range. It was noted that some antibacterial compounds show good inhibitory effects on all three bacterial CAs. CA inhibitors belonging to other classes may be synthesized and tested on VchCAs to harness cholera.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对霍乱弧菌酶的抗菌碳酸酐酶抑制剂。
导言霍乱是一种由霍乱弧菌引起的细菌性腹泻疾病,霍乱弧菌会产生霍乱毒素(CT)。除了改善水质卫生外,人们还开发了口服霍乱疫苗来控制感染。此外,补液和抗生素疗法也是霍乱的辅助治疗策略。ToxT 调控蛋白可激活 CT 基因的转录,而碳酸氢盐(HCO3-)可增强 CT 基因的转录:本综述深入研究了霍乱弧菌的基因组蓝图,其中编码了 α-、β- 和 γ-碳酸酐酶(CAs)。我们探讨了CA如何对霍乱弧菌的致病性起作用,并讨论了CA抑制剂在减轻该疾病影响方面的潜力:CA抑制剂可以降低细菌的致病力,控制霍乱。在此,我们回顾了所有报道的 CA 抑制剂,注意到与 β-CA 家族和 γ-CA 家族(VchCAβ 和 VchCAγ)相比,霍乱弧菌中的α-CA(VchCAα)是最有效的抑制酶。在 CA 抑制剂中,酰基硒苯磺酰胺类和简单/异芳香族磺酰胺类是 nM 范围内最佳的 VchCA 抑制剂。我们注意到,一些抗菌化合物对所有三种细菌 CA 都有很好的抑制作用。可以合成其他类别的 CA 抑制剂,并对 VchCA 进行测试,以控制霍乱。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.90
自引率
1.70%
发文量
58
审稿时长
3 months
期刊介绍: The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.
期刊最新文献
Targeted therapeutic strategies for the kidney. Advantages and disadvantages of targeting senescent endothelial cells in cardiovascular and cerebrovascular diseases based on small extracellular vesicles. Potential molecular targets for the pharmacologic management of non-traumatic osteonecrosis. What is holding back preclinical GPR119 agonists from their potential as the therapeutics of type 2 diabetes? Targeting the TRPV1 pain pathway in osteoarthritis of the knee.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1